Hookipa Q1 net loss $18.0M; cash rises to $141.8M on Gilead deal

HOOKIPA Pharma Inc.

2022-Q1 EPS reported -$0.40 revenue$1,445,000

Cash, equivalents and restricted cash $141.8M (Dec 2021: $66.9M) from Gilead collaboration and follow-on financing.
Revenue $1.4M vs $5.3M Q1 2021; $19M in milestone/initiation fees deferred for future recognition.
R&D expenses $16.6M (down from $20.2M); net loss $18.0M vs $17.2M in prior-year quarter.
Gilead HIV program advanced: $4M milestone, $15M initiation fee, $35M equity commitment; up to $237M milestones plus royalties.
HB-200 Phase 1 data due mid-2022; Phase 2 combo with pembrolizumab data in 2H 2022; prostate cancer IND expected Q3 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.